Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Part of paid clinical trials in Duarte, California.

Sponsor
University of Washington
Study ID
NCT04472338
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
40 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    Undergo collection of blood, urine, and/or tissue samples
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Quality-of-Life Assessment — OTHER
    Ancillary studies
  • Questionnaire Administration — OTHER
    Ancillary studies

Study Details

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Key Dates

Start date
May 21, 2020
Status verified
May 2026
Primary completion
Aug 31, 2030
Completion
Aug 31, 2030

Study Design

Enrollment
450 participants (estimated)

Arms

  • Arm: Screening (biospecimen collection)
    Participants undergo collection of blood, urine, and/or tissue samples every 12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 12 months after completion of curative therapy.

Primary Outcome Measure

Positive predictive values (PPVs) of age-based prostate specific antigen (PSA) thresholds [ Time Frame: Up to 10 years ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010
Joanne Jeter, MD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Matthew Cooperberg, MD, MPH (PRINCIPAL_INVESTIGATOR)
NorthwesternChicagoIllinois60611
Sophia Kallas
[email protected]
Edward Schaeffer, MD, PhD (SUB_INVESTIGATOR)
Hiten Patel, MD, MPH (PRINCIPAL_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02114
Keyan Salari, MD, PhD (PRINCIPAL_INVESTIGATOR)
OHSU Knight Cancer InstitutePortlandOregon97239
Alexandra Sokolova, MD
[email protected]
503-418-8150
Alexandra Sokolova, MD (PRINCIPAL_INVESTIGATOR)
University of Pennsylvania/Abramson Cancer CenterPhiladelphiaPennsylvania19104
Kara Maxwell, MD, PhD
[email protected]
215-615-3004
Kara Maxwell, MD, PhD (PRINCIPAL_INVESTIGATOR)
University of Texas Health Science Center at San AntonioSan AntonioTexas78229-
Fred Hutch/University of Washington Cancer ConsortiumSeattleWashington98109
Study Team Coordinator
[email protected]
206-210-4040
Heather H. Cheng, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Duarte, CA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
City of Hope· Duarte, CAUniversity of California, San Francisco· San Francisco, CANorthwestern· Chicago, ILMassachusetts General Hospital· Boston, MAOHSU Knight Cancer Institute· Portland, ORUniversity of Pennsylvania/Abramson Cancer Center· Philadelphia, PA

Related Studies